- Home
- HITI vs NBP Comparison
HITI vs NBP Comparison
Compare HITI & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HITI | NBP |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.6M | 205.9M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HITI | NBP |
|---|---|---|
| Price | $2.69 | $1.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $4.67 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 749.3K | 571.9K |
| Earning Date | 09-14-2026 | 08-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.52 | N/A |
| Revenue Next Year | $10.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.02 | $1.32 |
| 52 Week High | $3.80 | $5.19 |
Technical Indicators
Market Signals| Indicator | HITI | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 55.89 | 28.73 |
| Support Level | $2.29 | N/A |
| Resistance Level | $2.88 | $1.67 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 63.51 | 19.40 |
Price Performance
Historical ComparisonAbout HITI High Tide Inc.
High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically integrated company in the Canadian cannabis market with various brands in its portfolio such as Canna Cabana, Fastendr, Queen of Bud, Grasscity, Daily High Club, and others. The company's reportable operating segments are: Bricks and mortar, which generates maximum revenue, and E-commerce. Geographically, it derives maximum revenue from its business in Canada, followed by the United States of America, and other international markets.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.